Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme.
- 3 June 1989
- Vol. 298 (6686) , 1483-1486
- https://doi.org/10.1136/bmj.298.6686.1483
Abstract
OBJECTIVE--To evaluate the effect of support with human chorionic gonadotrophin in the luteal phase in women taking part in an in vitro fertilisation programme after buserelin and human menopausal gonadotrophin were used to hyperstimulate their ovaries. DESIGN--Controlled group comparison. SETTING--Outpatient department of a private hospital. PATIENTS--115 Women with indications for in vitro fertilisation, all of whom had at least one embryo transferred. INTERVENTIONS--After suppression of the pituitary with buserelin the ovaries of all the women were stimulated with human menopausal gonadotrophin on day 4 of the luteal phase. Human chorionic gonadotrophin (10,000 IU) was given to induce ovulation, and oocytes were recovered 34 hours later. Embryos were transferred 46 to 48 hours after insemination. Women who had received the 10,000 IU of human chorionic gonadotrophin on a date that was an uneven number (n = 61) were allocated to receive support doses of 2500 IU human chorionic gonadotrophin three and six days after that date. The remaining 54 women did not receive hormonal support. END POINT--Determination of the rates of pregnancy. MEASUREMENTS and main results--Support with human chorionic gonadotrophin did not significantly alter the progesterone or oestradiol concentrations in the early or mid-luteal phase. The mean (range) progesterone concentrations in the late luteal phase in women who did not become pregnant were, however, significantly higher in those who received support (16(9-110) nmol/l nu 8(4-46) nmol/l), and the luteal phase was significantly longer in this group (14 days nu 12 days). The rate of pregnancy was significantly higher in the women who received support than in those who did not (25/61 nu 8/54). CONCLUSIONS--When buserelin and human menopausal gonadotrophin are used to hyperstimulate ovaries support with human chorionic gonadotrophin in the luteal phase has a beneficial effect on in vitro fertilisation.This publication has 29 references indexed in Scilit:
- Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormoneBMJ, 1988
- A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transferFertility and Sterility, 1988
- The effect of progesterone supplementation around the time of oocyte recovery in patients superovulated for in vitro fertilizationFertility and Sterility, 1986
- Effects of low-dose human chorionic gonadotropin on corpus luteum function after embryo transferJournal of Assisted Reproduction and Genetics, 1985
- Maternal Recognition of Pregnancy prior to Implantation: Methods for Monitoring Embryonic Viability in Vitro and in VivoAnnals of the New York Academy of Sciences, 1985
- Ovarian Stimulation Regimens in an in Vitro Fertilization Program: A Comparative AnalysisAnnals of the New York Academy of Sciences, 1985
- Altered follicular development in clomiphene citrate versus human menopausal gonadotropin-stimulated cycles for in vitro fertilizationFertility and Sterility, 1985
- Three years of in vitro fertilization at NorfolkFertility and Sterility, 1984
- Luteal phase serum estradiol and progesterone in in vitro fertilizationFertility and Sterility, 1984
- The significance of the human corpus luteum in pregnancy maintenanceAmerican Journal of Obstetrics and Gynecology, 1972